JP2017525337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525337A5 JP2017525337A5 JP2016573588A JP2016573588A JP2017525337A5 JP 2017525337 A5 JP2017525337 A5 JP 2017525337A5 JP 2016573588 A JP2016573588 A JP 2016573588A JP 2016573588 A JP2016573588 A JP 2016573588A JP 2017525337 A5 JP2017525337 A5 JP 2017525337A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bap1
- biomarker
- expression
- ezh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims description 70
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims description 68
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 claims description 68
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 claims description 68
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 claims description 68
- 239000000090 biomarker Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 49
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 36
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 36
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 18
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 claims description 13
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 claims description 13
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 10
- 230000001093 anti-cancer Effects 0.000 claims description 10
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 10
- 201000005969 Uveal melanoma Diseases 0.000 claims description 9
- 239000013643 reference control Substances 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 6
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 6
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 238000003491 array Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 6
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 6
- 238000010166 immunofluorescence Methods 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 210000002752 melanocyte Anatomy 0.000 claims description 6
- 206010027191 meningioma Diseases 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 208000007312 paraganglioma Diseases 0.000 claims description 6
- 201000008261 skin carcinoma Diseases 0.000 claims description 6
- 201000003708 skin melanoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 101000966290 Homo sapiens Lethal(3)malignant brain tumor-like protein 2 Proteins 0.000 claims description 2
- 102100040546 Lethal(3)malignant brain tumor-like protein 2 Human genes 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000003752 polymerase chain reaction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014594P | 2014-06-19 | 2014-06-19 | |
| US62/014,594 | 2014-06-19 | ||
| PCT/US2015/036677 WO2015196064A1 (en) | 2014-06-19 | 2015-06-19 | Biomarkers for response to ezh2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525337A JP2017525337A (ja) | 2017-09-07 |
| JP2017525337A5 true JP2017525337A5 (enExample) | 2018-07-26 |
| JP6684230B2 JP6684230B2 (ja) | 2020-04-22 |
Family
ID=54936135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573588A Expired - Fee Related JP6684230B2 (ja) | 2014-06-19 | 2015-06-19 | Ｅｚｈ２阻害剤への応答についてのバイオマーカー |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170138946A1 (enExample) |
| EP (1) | EP3158086B1 (enExample) |
| JP (1) | JP6684230B2 (enExample) |
| KR (1) | KR20170020463A (enExample) |
| CN (1) | CN106795561B (enExample) |
| AU (1) | AU2015276899B2 (enExample) |
| BR (1) | BR112016029911A2 (enExample) |
| CA (1) | CA2952285A1 (enExample) |
| EA (1) | EA036889B1 (enExample) |
| ES (1) | ES2870096T3 (enExample) |
| IL (1) | IL249443B (enExample) |
| MX (1) | MX384423B (enExample) |
| SG (2) | SG10202007972SA (enExample) |
| WO (1) | WO2015196064A1 (enExample) |
| ZA (1) | ZA201608555B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US12442042B2 (en) | 2016-02-16 | 2025-10-14 | Agency For Science, Technology And Research | Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma |
| GB201615842D0 (en) * | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| WO2020247130A1 (en) * | 2019-06-03 | 2020-12-10 | Icahn School Of Medicine At Mount Sinai | Compounds and methods for inhibiting cancers via rest inhibition |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN118161615B (zh) * | 2024-03-19 | 2025-08-12 | 山东大学齐鲁医院 | Phf20抑制剂在制备抗皮肤癌药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US548257A (en) | 1895-10-22 | Hay rake and loader | ||
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US5932422A (en) * | 1997-11-14 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
| US6218114B1 (en) | 1998-03-27 | 2001-04-17 | Academia Sinica | Methods for detecting differentially expressed genes |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| WO2001055454A1 (en) | 2000-01-28 | 2001-08-02 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| EP1385998A1 (en) | 2001-04-19 | 2004-02-04 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
| AU2001286171B2 (en) | 2001-05-25 | 2008-01-10 | Serono Genetics Institute S.A. | Human CDNAs and proteins and uses thereof |
| US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
| US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
| EP1425695A2 (en) | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
| AU2003213054A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
| WO2003091735A1 (en) | 2002-04-23 | 2003-11-06 | Millipore Corporation | Sample preparation of biological fluids for proteomic applications |
| WO2007001986A2 (en) | 2005-06-20 | 2007-01-04 | Yuling Luo | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20140011696A1 (en) * | 2011-02-16 | 2014-01-09 | Thomas Wiesner | Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia |
| WO2012144220A1 (en) * | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
| BR112014007603A2 (pt) * | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| EP2825161B1 (en) | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
-
2015
- 2015-06-19 MX MX2016017097A patent/MX384423B/es unknown
- 2015-06-19 CN CN201580044280.9A patent/CN106795561B/zh not_active Expired - Fee Related
- 2015-06-19 EP EP15809484.7A patent/EP3158086B1/en active Active
- 2015-06-19 EA EA201692497A patent/EA036889B1/ru unknown
- 2015-06-19 SG SG10202007972SA patent/SG10202007972SA/en unknown
- 2015-06-19 BR BR112016029911A patent/BR112016029911A2/pt not_active Application Discontinuation
- 2015-06-19 AU AU2015276899A patent/AU2015276899B2/en not_active Ceased
- 2015-06-19 CA CA2952285A patent/CA2952285A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036677 patent/WO2015196064A1/en not_active Ceased
- 2015-06-19 SG SG11201610610YA patent/SG11201610610YA/en unknown
- 2015-06-19 ES ES15809484T patent/ES2870096T3/es active Active
- 2015-06-19 JP JP2016573588A patent/JP6684230B2/ja not_active Expired - Fee Related
- 2015-06-19 KR KR1020177001353A patent/KR20170020463A/ko not_active Abandoned
-
2016
- 2016-12-07 IL IL249443A patent/IL249443B/en unknown
- 2016-12-12 ZA ZA2016/08555A patent/ZA201608555B/en unknown
- 2016-12-15 US US15/380,807 patent/US20170138946A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525337A5 (enExample) | ||
| Reece et al. | The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer | |
| Dong et al. | RETRACTED ARTICLE: SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88 | |
| Luo et al. | Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression | |
| Jin et al. | The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy | |
| Tang et al. | LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer | |
| Zhang et al. | Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma | |
| Li et al. | Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma | |
| Xie et al. | Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population | |
| WO2012153187A4 (en) | Markers for cancer prognosis and therapy and methods of use | |
| KR102585110B1 (ko) | 암 예후의 판정 | |
| JP2017516458A5 (enExample) | ||
| Zhuang et al. | Up-regulation of plasma miR-23b is associated with poor prognosis of gastric cancer | |
| Liao et al. | Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation | |
| Zhou et al. | Expression of chemokine XCL2 and CX3CL1 in lung cancer | |
| Wu et al. | Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation | |
| Li et al. | Plasma miRNA-506 as a prognostic biomarker for esophageal squamous cell carcinoma | |
| Pavlidou et al. | Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR | |
| Jing et al. | Prognostic and diagnostic significance of SDPR-Cavin-2 in hepatocellular carcinoma | |
| Matsusaka et al. | Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy | |
| Song et al. | Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma | |
| Sudoyo et al. | Increased CD8 tumor infiltrating lymphocytes in colorectal cancer microenvironment supports an adaptive immune resistance mechanism of PD-L1 expression | |
| Cui et al. | Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab | |
| Yang et al. | Identification of a functional polymorphism within the 3′-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma | |
| Heinzelmann et al. | 4-miRNA score predicts the individual metastatic risk of renal cell carcinoma patients |